Microba Life Sciences (ASX:MAP) Total Long-Term Assets: A$27.17 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Microba Life Sciences Total Long-Term Assets?

Microba Life Sciences ASX:MAP +4.76% Total Long-Term Assets is A$27.17 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Microba Life Sciences's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$27.17 Mil.

Microba Life Sciences Total Long-Term Assets Related Terms

Microba Life Sciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Total Long-Term Assets Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
3.66 5.43 25.79 28.44

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only 22.72 25.79 28.34 28.44 27.17

Microba Life Sciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$27.17 Mil mean?
Microba Life Sciences (ASX:MAP) has a Total Long-Term Assets of A$27.17 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' Total Long-Term Assets too high?
Microba Life Sciences' current Total Long-Term Assets is A$27.17 Mil.
How does Microba Life Sciences' Total Long-Term Assets compare to TMO and DHR?
Microba Life Sciences' Total Long-Term Assets of A$27.17 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Diagnostics & Research company?
A good Total Long-Term Assets depends on the Medical Diagnostics & Research industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Total Long-Term Assets is A$27.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.24, compared to a current price of A$0.04 — trading 81.7% below its estimated fair value. The current Total Long-Term Assets is A$27.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Total Long-Term Assets is A$27.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.